Oncology

Adjuvant immunotherapy induced improved survival compared with those who did not in patients with stage 3 melanoma, according to data from a large real-world database.

RO7198457 in combination with atezolizumab induced significant levels of neoantigen-specific immune responses with a manageable safety profile in patients with locally advanced or metastatic solid tumors.

The expert from the American Cancer Society spoke about updated guidelines published recently regarding recommendations on diet and physical activity for cancer prevention.

The FDA approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high solid tumors.

Experts discuss the case of a 56-year-old white man who presents with multiple immune-related adverse events

A clinically applicable mathematical model was developed by researchers to predict outcomes to immunotherapy for patients with cancer previously treated with anti–CTLA-4 or anti–PD-1/PD-L1 antibodies.

Interim data from cohort B of KEYNOTE-555, a phase I trial evaluating a 400 mg every 6-week dosing regimen of pembrolizumab in patients with metastatic melanoma, demonstrated a consistent benefit-risk profile.

The FDA approved an additional recommended dose of 400 mg pembrolizumab (Keytruda) every 6 weeks across all adult indications.

The study found that pembrolizumab has activity in brain metastases from non-small cell lung cancer that is similar to its systemic activity and can result in prolonged survival in a subset of patients.

A recent study determined 4 distinct long noncoding RNA-based immune classes for patients with cancer and provided scores for integration into multiomic panels for precision immunotherapy.

Researchers found that the potential availability of CAR T-cell therapies for large B-cell lymphomas with lower adverse event rates that are suitable for outpatient administration may reduce the total costs of care.

The FDA cleared the investigational new drug (IND) application for the use of CYNK-001 in adults with COVID-19.

Researchers analyzed a patient population with stage IV melanoma and found no difference in the rate of surgical resection with the use of immunotherapy between the checkpoint inhibitor era and pre-checkpoint inhibitor era.

Dylan Essner discussed the implementation of documentation tools and CRS, ICANS and ICE flow sheets within CAR T-cell therapy.

The associate director for clinical research at the Washington University School of Medicine spoke about the value and challenges of using EMRs in CAR T-cell therapy.

Researchers suggested that patients with non-small cell lung cancer (NSCLC) who have higher measures of tumor mutations that appear in a blood test generally have a better clinical response to PD-1-based immunotherapy than those with a lower measure of mutations.

Karen Kelly, MD, sat down to discuss her presentation on when to start immunotherapy in a real world, patient setting.

Walter Curran, MD, detailed his presentation on immunotherapy and radiation therapy, and how integrating the 2 treatment options presents an exciting opportunity moving forward.

Gilberto Lopes, MD, MBA, FAMS, discussed his presentation about when to stop immunotherapy treatments for patients with lung cancer.

Rogerio Lilenbaum, MD, talked about the state of lung cancer in regards to immunotherapy and targeted therapy at the 17th Annual Winter Lung Conference in Miami Beach, Florida.

According to the researchers, these data suggest that checkpoint blockade in women with early-stage, high-risk, ERBB2-negative breast cancer is very likely to succeed in a phase III trial.

The FDA granted 2 Fast Track designations for ALX148 for the first-line treatment of patients with head and neck squamous cell carcinoma, and for the second-line treatment of patients with HER2-positive gastric or gastroesophageal junction carcinoma.

In this study, most clinical combinations including PD-1 or PD-L1 inhibitors demonstrated more clinical activity than the monotherapy activity of the checkpoint inhibitor alone.

The associate professor of clinical medicine discussed the main side effects of CAR T-cell therapies when treating multiple myeloma, and how to combat them.

Patients with either relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with CAR NK cells had a response without the development of cytokine release syndrome, neurotoxicity, or graft-versus-host disease.